To study the mechanisms of placenta function and the role of extracellular vesicles (EVs) in pregnancy, it is necessary to develop an ex vivo system that retains placental cytoarchitecture and the primary metabolic aspects, in particular the release of EVs and soluble factors. Here, we developed such a system and investigated the pattern of secretion of cytokines, growth factors, and extracellular vesicles by placental villous and amnion tissues ex vivo. 
| INTRODUC TI ON
The placenta plays a critical role in fetal growth and development and orchestrates major maternal adaptations of pregnancy such as carbohydrate intolerance [1] [2] [3] [4] [5] and immune adaptations. Placental dysfunction has been implicated in major complications of pregnancy such as preeclampsia, fetal growth restriction, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] fetal death, [73] [74] [75] [76] [77] [78] [79] [80] and preterm labor. [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] The placenta has also been considered as the center of the chronic disease universe. 91, 92 The study of human placentae in vivo is challenging and has significant restrictions. Animal models have been useful, although
there are fundamental differences in placentation among mammals. [93] [94] [95] [96] [97] Many studies of human placenta utilize isolated primary cells or placenta-derived cell lines. [98] [99] [100] [101] While major discoveries have emerged from such studies, [102] [103] [104] isolated cells do not adequately recapitulate important aspects of tissue function related to cellcell communications in vivo. This is the rationale to develop threedimensional models that maintain the cellular relationships ex vivo.
Such three-dimensional models have proven to be of major value in investigating cancer development, [105] [106] [107] [108] [109] viral pathogenesis, [110] [111] [112] [113] and testing anticancer 114 and antiviral compounds 115 under controlled laboratory conditions.
It is now increasingly apparent that the maternal-fetal dialogue is more complex than previously recognized. [116] [117] [118] [119] In addition to many soluble factors, such as hormones and cytokines implicated in this communication, it is now recognized that extracellular vesicles (EVs) can also mediate crosstalk between the feto-placental unit and the mother. [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] Extracellular vesicles carry lipids, proteins, and miRNA that can convey information about the status of the fetus and placenta. [132] [133] [134] Moreover, EVs carry immune mediators (eg, cytokines) that facilitate cell-to-cell communication, which are present on both the surface and inside the microvesicles. [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] To study the mechanisms of placental function and the role of EVs in pregnancy, it is necessary to develop an ex vivo system that retains placental cytoarchitecture and continues to release EVs and soluble factors under controlled laboratory conditions. Here,
we report on such a system. Using nanotechnology, we analyzed individual EVs released by placental tissues ex vivo and assessed EV-bound and EV-encapsulated cytokines. Establishment and benchmarking this placental ex vivo system provides a basis to study the nature of various placental disorders and, in particular, the release of EVs and cytokines. Their release by the syncytiotrophoblast into the maternal circulation has been proposed as a placental liquid biopsy, which can provide insight into the functional status of the organ and may be a source of biomarkers to predict pregnancy complications. 146 Herein, we report a system of ex vivo placental villous and amnion tissues that can be used as an adequate model to study physiological and pathological processes during normal and complicated pregnancies.
| ME THODS

| Sample preparation and storage
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| Cytokine measurement
We previously developed an in-house multiplexed bead-based assay for measurement of the following cytokines/growth factors: IL-1α, IL- Magnetic beads (Luminex, Austin, TX) with distinct spectral signatures (regions) were coupled to cytokine specific capture antibodies, according to manufacturer's recommendations, and stored at 4°C. All antibody pairs were verified to be free of cross reactivity.
Standards and samples were combined with bead mixtures and incubated overnight at 4°C. Intact EV samples and lysed EV samples, to which Triton X was added at a final concentration of 1%, were run in separate wells. Plates were washed two times and incubated with mixtures of polyclonal biotinylated anticytokine antibodies for one hour at room temperature. Plates were washed twice and incubated for 25 minutes with 16 μg/mL streptavidin-phycoerythrin in PBS.
Plates were washed twice, and beads were resuspended in PBS and read on a Luminex 200 analyzer with acquisition of 100 beads for each region and analyzed using Bioplex Manager software (BioRad, Hercules, CA). Cytokine concentrations were determined using 5P regression algorithms. ebeads (Thermo Fisher) were added to tubes for EV quantification.
| EV labeling and capture
All antibodies were tested on EV/MNP complexes singly and in combination to verify that antibodies bound with the same efficiency and that spectral overlap could be compensated.
| EV flow cytometry analysis
Purified complexes were acquired at low speed on an LSRII (BD 
| Measurement of EV-associated cytokines
Extracellular vesicles were captured as above using MNPs coupled to mouse anti-human antibodies to PLAP (8B6, Thermo 
| Statistical analysis
We conducted statistical analysis using JMP10 (SAS Institute, Cary, NC). Results are represented as means ± standard error of the mean (SEM). The statistical differences were evaluated with paired Student's t test. All hypothesis tests were two-tailed and a P value of ≤.05 defined statistical significance.
| RE SULTS
| Ex vivo tissue viability and function
| Histology
Samples of the villus tree and amnion were dissected and cultured as described in the Methods section. Tissue samples were collected at days 1, 7, and 14 of culture, fixed, paraffin-embedded, sectioned, and H&E stained (Figure 1 ). At the start of culture, chorionic villi were viable and maintained normal morphology with well-preserved syncytiotrophoblasts, intact blood vessels, and a lack of karyorrhexis; amnion tissue was well preserved. At day 7, much of the syncytiotrophoblast appeared viable and well preserved, with focal areas of early degenerative changes in the form of karyorrhectic debris in F I G U R E 1 Placental villous and amnion tissue explants maintain their cytoarchitecture. H&E sections of placental villous explants at days 1 (A), 7 (B), and 14 (C) of culture (one representative tissue of 10). Villi maintained normal morphology with well-preserved syncytiotrophoblasts and blood vessels with some focal degenerative changes. H&E sections of amnion explants at days 1 (D), 7 (E), and 14 (F) 14 of culture also show well-preserved tissue with focal degenerative changes at day 14
blood vessels and villous stromal-vascular karyorrhexis. Most of the amnion appeared well preserved and viable at day 7. By day 14, placental villous tissue showed slightly more pronounced karyorrhexis and degeneration of syncytiotrophoblast than at day 7. Amnion tissue at day 14 also showed mild degenerative changes in the form of pyknosis.
| Cytokine production
The release of cytokines by villi and amnion cultures over the entire culture period was determined using in-house designed multiplexed bead-based assays. 150 These assays revealed that cytokines are steadily produced in both placental villous and amnion cultures ( Table S1 ).
Amnion explants, similar to villi explants, produced cytokines constantly over the duration of the culture period ( Figure 2C ). Amnion and villous explants also produced large amounts of the pro-inflammatory cytokines IL-6, IL-8, GRO-α, IP-10, and MCP-1 as well as CRP and TRAIL. Such explants also produced the antimicrobial proteins calgranulin C and lactoferrin as well as smaller amounts of calgranulin A.
Moreover, the explants produced the prototypic alarmin HMGB1 as well as IL-10, IL-13, IL-16, IL-33, MIP-1α, MIP-1β, MIP-3α, MIF, CXCL6, and smaller amounts of ITAC, RANTES, and CXCL9 (see Table S1 ).
| Production of growth factors, and angiogenic and anti-angiogenic factors
The release of other growth factors, angiogenic factors, antiangiogenic factors, and hormones was determined by multiplexed bead assays. Both villi and amnion explants also continuously produced these factors over the duration of the culture period Table S2 .
Amnion explants produced large amounts of many of the same growth and angiogenic factors as villi explants including adiponectin,
angiogenin, fibronectin, galectin-1, IGFBP1, IL-1Ra, IL-27, serpin E1, F I G U R E 2 Placental villous and amnion tissue explants maintain cytokine and growth factor production throughout the culture period. Soluble cytokines, growth factors, and angiogenic and anti-angiogenic factors are produced by explants over the entire 14-day culture period (presented are average productions, mean ± SEM) as measured by multiplexed bead assays. Culture medium is replaced at each sampling time point. (A) Placental villous explants: amounts of cytokines released at days 1, 4, 7, 10, and 14, n = 10; (B) placental villous explants: amounts of growth factors released at days 1, 4, 7, 10, and 14, n = 10; (C) amnion explants: amounts of cytokines released at days 1, 4, 7, 10, and 14, n = 10; (D) amnion explants: amounts of growth factors released at days 1, 4, 7, 10, and 14, n = 10 TFPI, TIMP-1, VEGFR1, uPA, and uPAR, and the hormones hCG and PGE2 ( Figure 2D ; See Table S2 for complete list).
| Analysis of placental villous EVs
To analyze EVs specifically from syncytiotrophoblasts (STB) of the explants, magnetic nanoparticles (MNPs) coupled to anti-PLAP antibody, an antigen specific to STB, 123, [152] [153] [154] [155] were used. EVs were labeled with BODIPY-FL as described in Methods. Among several commercially available anti-PLAP antibodies, we selected one (clone 8B6) that after its coupling to MNPs was specific in capture of STBgenerated EVs and captured EVs most efficiently. We analyzed the STB-generated EVs for other antigens that have been described on STBs or STB EVs.
| Selection of PLAP antibodies for capture of syncytiotrophoblast EVs
We coupled two clones of PLAP antibodies to MNPs and cap- 
| Specificity of EV capture
We further verified the specificity of our anti-PLAP-MNPs by incubation with amnion explant supernatants which should not contain PLAP + EVs 156 and found they captured on average 4.7% ± 0.5% of total EVs (n = 3). That was not different from the amount captured with control mouse IgG isotype MNPs: With these MNPs, we captured from the placental villous tissue supernatants 4.8% ± 1.1% of EVs that were captured by specific anti-PLAP-MNPs (n = 3).
| The lack of non-STB antigens on anti-PLAPcaptured STB-generated EVs
To further confirm specificity of the PLAP-captured EVs, we captured EVs from villous samples pooled from multiple donors and stained for CD31, CD41, CD45, and HLA-ABC, all of which should be absent on STB EVs. [156] [157] [158] All antibodies were labeled with the same fluorophore and collected into a single "dump" gate. We found that they were present on only 1.6% ± 0.5% of captured EVs (n = 3).
For the remaining experiments, we included only HLA-ABC and used the lack of this marker as an additional criterion for STB EVs. Single staining for HLA-ABC on EVs captured by anti-PLAP-MNPs revealed 0.7% ± 0.3% of total EVs (n = 3).
| Syncytiotrophoblast markers on PLAPpositive EVs
Next, we evaluated the distribution of several "phenotypic" markers on the EVs captured by MNPs through PLAP. We chose markers which have been previously described in the literature as being surface markers either of STB themselves or of the STB-generated Flow cytometry analysis revealed that CD200 had the highest expression on PLAP-MNPs-captured EVs, being present on 67.3% ± 3.1% of vesicles at day 1, and syncytin-1 was the lowest at 1.7% ± 0.2%. The other markers were expressed on 24%-34% of vesicles ( Figure 3A ). EV size was estimated using Megamix SSC beads. The vesicles formed a continuum rather than discreet populations, but small vesicles of the size 200 nm or less were the most plentiful and over 500 nm the least common ( Figure 3B ).
The distribution of the markers varied with vesicles of different sizes ( Figure 3C -H). Only CD200 was highly expressed (58.8% ± 4.4%) at day 1 on small vesicles (of the size of 200 nm or less), while all other markers were present at lower levels on these small vesicles (0.5%-18.4%). Levels of CD51, CD63, CD105, and CD274 were highest on vesicles of the size of 250-500 nm, and syncytin-1 was highest on vesicles of the size above 500 nm.
We analyzed co-expression of markers on individual vesicles and found CD51, CD63, CD105, and CD274 were most often co-expressed with CD200, the most highly expressed marker on the placental villous EVs ( Figure S2 ). Syncytin-1 was the least coexpressed molecule, but was most often co-expressed with CD105.
Assessment of PLAP-captured vesicles over time showed
that the total number of vesicles decreased throughout the culture period. Total EVs at day 1 were 1.91 ± 3.3 × 10 6 EVs/mL and declined to 9.4 ± 1.7 × 10 4 EVs/mL by day 14 (see Table S3 for EV counts). The distribution of EVs in different size ranges shifted slightly over time ( Figure 3B ). The amount of small vesicles (≤200 nm) decreased over time, starting at 52.1% ± 3.0% at day 1 and dropping to 25.5% ± 3.6% at day 14, whereas vesicles of all other size ranges increased slightly in percentage with length of culture.
The amount of PLAP-captured vesicles expressing each marker was similar at days 1 and 4, but decreased slightly by day 7 and further by day 14, except for syncytin-1 expressing EVs, which increased in over time ( Figure 3C-H and all other markers that increased slightly over time ( Figure S2A ).
These results demonstrate that placental villous explants produce EVs carrying typical STB markers throughout the culture period. EVs expressing each marker maintained a similar 
| Analysis of amnion EVs
In parallel to the analysis of the STB-released EVs, we analyzed the EVs released by amnion explants by identification of specific cellular antigens on these EVs. EVs were labeled with BODIPY-FL as described in Methods. The main cells of interest in amnion explants
were amnion epithelial cells (AECs; as they are in contact with amniotic fluid, thus likely to be involved in fetal communication), as well as the underlying amnion mesenchymal stem cells (AMSCs). We used
MNPs coupled to antibodies specific to antigens that these cells carry. As CD90 is a marker expressed by both AECs and AMSCs, 163 we investigated this protein as a target for capture with MNPs using anti-CD90 antibodies.
| Optimizing capture of amnion EVs
We incubated amnion explant culture supernatants with anti-CD90
MNPs to capture EVs and compared them to capture with anti-CD63,
anti-CD9, and anti-HLA-ABC-coupled MNPs. MNPs coupled to CD9, HLA-ABC and to CD63 captured 113% ± 5.3%, 75.8% ± 16.7%, and 93.7% ± 11.8% of that of coupled to CD90, respectively (n = 3). As CD90 is the most exclusive marker for our cells of interest, we used anti-CD90 MNPs for our further experiments.
| Specificity of EV capture
Next, we verified whether anti-CD90 MNPs specifically capture only EVs carrying CD90. As a negative control, we used these MNPs to capture EVs from placental villous culture supernatants (which should release very few EVs carrying CD90, potentially from placental MSCs 164 ). We found that these MNPs captured on average only 2.5% ± 0.8% of total EVs (n = 3). We also confirmed MNP specificity by incubating amnion tissue supernatants with mouse IgG isotype MNPs, which captured 6.3% ± 1.4% of EVs compared to anti-CD90 MNPs (n = 3).
| Lack of irrelevant antigens on AEC-generated EVs
We captured EVs from amnion samples from multiple donors with anti-CD90 MNPs and stained captured EVs for CD31, CD41, CD45, and HLA-DR, which should not be present on EVs of this origin. 165 All antibodies were labeled with the same fluorophore, APC-Cy7 and collected into a single "dump" gate. Our staining revealed that these markers were present on only 4.8% ± 0.5% of captured EVs. Further analysis of amnion EVs included only antibodies against HLA-DR, which contributed 2.8% ± 0.3% of total EVs (n = 3), and this population was excluded from flow cytometry analysis.
| AEC and AMSC markers are revealed on amnion explant EVs
The distribution on EVs of several "phenotypic" markers expressed by AECs or AMSCs, 166, 167 namely CD29, CD44, CD105, CD140b, CD324, and CD326, were determined. EVs were labeled with BODIPY-FL, captured with anti-CD90 MNPs, and stained with antibodies to the above markers (in addition to HLA-DR). The labeled EV-MNP complexes were washed on magnetic columns, eluted, and then acquired on a flow cytometer set to threshold on the BODIPY-FL label. Any vesicles positive for HLA-DR were excluded and the remainder quantified by size, estimated by Megamix SSC beads, and expression of the markers of interest (see Figure S1 for gating strategy).
First, we evaluated EVs from amnion culture supernatants at day 1 of culture ( Figure 4A ). We found that CD105 was the most highly expressed marker being present on 18.5% ± 0.7% of all captured EVs, and CD140b was the least expressed on 4.0% ± 0.6%
of EVs (n = 10). CD44, CD326, CD324, and CD29 were on approximately on 15%, 12%, 10%, and 9% of EVs, respectively. EVs were equally distributed among most size ranges, except EVs of 200 nm or less which were expressed on 4.6% ± 0.6% of all EVs ( Figure 4B ). Most markers were more likely to be on larger vesicles ( Figure 4C -H). CD105 was highest on vesicles of the size of 500 nm and over, CD140b was much higher on vesicles with the size over 500 nm, and CD44, CD324, CD326, and CD29 were distributed more evenly between all size ranges except the smallest.
Evaluation of marker co-expression demonstrated that CD29
and CD44 were the most commonly found together (4.2% ± 0.7% of EVs at day 1), followed by CD140b and CD326 (3.1% ± 0.7% EVs at day 1; Figure S2B ).
Next, we investigated how the number of CD90-captured vesicles changed over time. Unlike PLAP-captured EVs from placental villous explants, the amount of amnion-generated vesicles captured with CD90-MNPs did not decrease over time. The total concentration of vesicles at day 1 was 9.5 ± 1.4 × 10 4 /mL and at day 14 was 9.9 ± 1.8 × 10 4 /mL (see Table S3 for all EV counts). The amount of amnion EVs remained constant over the entire culture period in all aspects: in size ranges of vesicles ( Figure 4B ), in the fractions of total EVs for each ( Figure 4C-H) , and for the fractions of double positive EVs ( Figure S2B ).
These results confirm that amnion explants continually produce
EVs representative of AECs and AMSCs over 14 days of culture.
| Analysis of EV-associated cytokines
| EVs from different cells carry different cytokines
We captured EVs from culture supernatants at day 4 with MNPs coupled with specific capture antibodies to investigate whether EVs with different surface markers (ie, generated by different cells) carry different cytokines.
| Placental villous EVs
Total EVs were isolated from placental villous culture supernatants using Exoquick TC™. From this isolate, we captured several types of EVs using anti-PLAP-coupled MNPs to capture STB-generated EVs, anti-CD31 MNPs to capture EVs generated by endothelial cells, and HLA-G to capture EVs released by cytotrophoblasts and placental MSCs. Following MNP capture, EVs were magnetically isolated as described in Methods, and the EV-associated cytokines and growth factors were evaluated. Surface-associated proteins were measured directly with multiplexed bead assays, and total EV proteins were measured after EVs were lysed. We then subtracted the surface quantity from the total to determine the internal protein concentrations. Table   S4 for EV cytokine concentrations). Overall, cytokines tended to be EV-encapsulated rather than on their surface ( Figure 5 ). HLA-Gcaptured EV had slightly more cytokines on their surface compared to anti-PLAP-or anti-CD31-captured EVs. PLAP-captured EVs carried significantly more IL-4, IL-16, MIG, and TGF-β compared to both other types of capture (P < .05, n = 5), and were located predominantly inside EVs ( Figure 5B ). CD31-captured EVs were significantly higher in MIP3α and CXCL6 compared to HLA-G-captured EVs only (P < .05, n = 5), and these were encapsulated ( Figure 5C ). HLA-Gcaptured EVs were higher than both other captures in GM-CSF, IP-10, and MIF (P < .05, n = 5), and these were both on the surface and encapsulated ( Figure 5D ).
| Amnion EVs
Total EVs were isolated from amnionic culture supernatants using Exoquick TC™. Amnion EVs were captured with anti-CD90 MNPs, to capture presumably EVs from both AECs and AMSCs, and HLA-G antibodies to capture EVs from selected cells, as HLA-G has been reported in various levels on AECs and only weakly on AMSCs. Also, many cytokines were associated with EV (see Table   S5) , and TGF-β than HLA-G-captured EVs (P < .05, n = 5) and most were predominantly inside ( Figure 6B ).
HLA-G captured the highest levels of calgranulin C, GM-CSF, MIF,
and MIP-1β compared to CD90-captured EVs (P < .05, n = 5), and most were internal to the EVs ( Figure 6C ).
| EVs from different cells carry different growth factors
Extracellular vesicles from placental villous tissue also contained several growth factors and angiogenic-related factors (see Table   S6 ). Activin A, adiponectin, endoglin, fibronectin, galectin-1, ICAM-1, IL-1RA, IL-27, MMP-9, PAPP-A, serpin E1, TFPI, TIMP-1, TREM-1, uPA, uPAR, and VEGFR2 were found in the greatest quantities, as well as hCG and PGE2. Similar to cytokines, these growth factors were predominantly encapsulated within EVs rather than on their surface (Figure 7) , although HLA-G-captured EVs had more surfaceassociated than the other two captures. PLAP-captured EVs had significantly higher amounts of EV-associated ADAM12, endoglin, and PIGF than either CD31-or HLA-G-captured EVs (P < .05, n = 5).
PIGF was mostly on the surface of EVs, whereas ADAM12 and endoglin were predominantly encapsulated ( Figure 7B-D) . CD31-captured EVs carried significantly higher amounts of internal IL-27
and TREM-1 than HLA-G EVs (P < .05, n = 5). HLA-G-captured EVs contained significantly more adiponectin, CD40L, EGF, FasL, fibronectin, galectin-1, PGE2, resistin, TFPI, TGF-β3, Tie-2, tissue factor, TREM-1, uPA, uPAR, VEGFR1, and VEGFR2 than both PLAP-and CD31-captured EVs (P < .05, n = 5).
Growth and angiogenic factors were also associated with amnion
EVs (see Table S7 ); and activin A, adiponectin, fibronectin, galectin-1, ICAM-1, IL-1Ra, PAPP-A, serpin E1, TFPI, TIMP-1, TREM-1, uPA, uPAR, and VEGFR1, as well as hCG and PGE2, were secreted in the highest amounts. Amnion EVs also carried most growth factors predominantly inside EVs, and HLA-G-captured EVs had slightly more surface growth factors than CD90 captured (Figure 8 ). CD90
MNPs-captured EVs had significantly higher amounts of PAPP-A,
and TREM-1 (P < .05, n = 5), with PAPP-A being predominantly inside and TREM-1 being both on the surface and inside ( Figure 8B ).
HLA-G captured significantly higher levels of adiponectin, CD40L, EGF, endoglin, FasL, galectin-1, ICAM-1, IGFBP1, IL-1Ra, PGE2, resistin, TFPI, TGF-β3, Tie-2, tissue factor, uPA, uPAR, VEGFR1, and VEGFR2 (P < .05, n = 5), much the same as HLA-G-captured villi EVs ( Figure 8C ).
| D ISCUSS I ON
| Previous studies of placental explants
Several techniques for maintaining placental explants have been described, [168] [169] [170] [171] with different models being useful for different purposes. Typically, placental tissues are immersed in the culture medium either free floating or supported by Matrigel™ or Millicell inserts. In these experiments, tissues remain viable up to 9 days and produce human chorionic gonadotropin (hCG) and placental lactogen. 172 Most of these models report that STBs are lost in the first 1-2 days of culture, but some regeneration was observed by 5-7 days.
173,174
Following the pioneer works of Hoffman et al, 175, 176 we developed cultures of ex vivo tissues maintained on collagen sponges at the medium/air interface to study HIV pathogenesis in human lymphoid, 177-181 cervico-vaginal, [182] [183] [184] and recto-sigmoid tissues, 185 and to investigate the physiology of atherosclerotic plaques 186,187 ex vivo.
A comparable culture method was used to study cytomegalovirus infection. 188 Here, we apply a similar technique to study placental tissue secretion of EVs, cytokines, and growth factors ex vivo.
| The establishment of a three-dimensional culture to study extracellular vesicles and cytokines
The purpose of the present study was to develop a laboratory model to study soluble factors and EVs generated by placental villous tissue. This is important since both EVs and soluble factors, in particular placental cytokines, 189, 190 
| Analysis of placental villous extracellular vesicles
We found that STB-specific EVs can be captured from placental villous culture supernatants using anti-PLAP-MNPs. PLAP is a sialoglycoprotein enzyme present almost exclusively on STBs and has been used as a marker of STB-derived EVs. 123, 153, 155 We first demonstrated specificity of capture by demonstrating that We assessed the PLAP-captured EVs for other surface proteins previously described to be expressed on STBs or on their EVs, CD51, CD63, CD105, CD200, CD274, and syncytin-1. All these proteins were found albeit in various quantities on PLAP-MNP-captured for instance, most markers were expressed on only a small percentage of small EVs, except for CD200. These differences may reflect differential function of these EVs. Whatever these functions are, the overall pattern of these antigens expressed on the different sizes of EVs remained constant' again demonstrating viability of the ex vivo tissues. Also, co-expression of the various markers remains fairly constant over time.
| Analysis of extracellular vesicles produced by amnion
Extracellular vesicles were also produced by amnion and were captured with anti-CD90 MNPs. CD90, a cell surface glycoprotein involved in cell adhesion, is expressed on both AECs and AMSCs, as well at varying levels on fibroblasts, neurons, and activated endothelial cells. 163, [247] [248] [249] [250] We confirmed specificity of capture by showing anti-CD90 MNPs captured very few EVs generated by placental villous tissue. Also, CD90 MNP-captured EVs lacked expression of markers that should not be present on amnion-generated EVs, including CD31, CD41, CD45, and HLA-DR. EVs were generated at constant levels throughout all the 14 days of culture and maintained the same size distributions. These EVs carried other proteins on their surface that have previously been described on AECs and AMSCs.
These included CD29, CD44, CD105, CD140b, CD324, and CD326, which are involved in cell-cell and cell-matrix interactions, cell adhesion, and migration. [251] [252] [253] CD29 (integrin beta-1) acts as a fibronectin receptor. 252 CD44 is a receptor for hyaluronic acid. 254 CD140b is a tyrosine kinase receptor for members of the platelet-derived growth factor family and a marker for naive AMSCs. 255 CD324 or E-cadherin is a regulator of epithelial junction formation. 256 CD326, also known as Ep-CAM, is an epithelial cell surface antigen. 
| Cytokines and other factors in EVs of different phenotypes
Here, we demonstrate that not only cytokines, but many other growth factors, and angiogenic and anti-angiogenic factors are associated with EVs from placental villous and amnion tissues. These factors can be on the EV surface or encapsulated within the vesicles.
In this study, we took this analysis one step further from the analysis of association of these factors with general EVs to their association with EVs that carry particular membrane proteins. Specifically, we captured EVs using MNPs coupled to antibodies that select for certain EV populations, and analyzed the cytokine and growth factor content of these EV fractions.
We found that placental villous EVs captured via PLAP, CD31, In amnion tissue, we specifically captured EVs using anti-CD90
and anti-HLA-G MNPs, analyzed their cytokine and growth fac- 
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